DyNAbind GmbH logo — Accelerating Drug Discovery

DyNAbind GmbH

Accelerating Drug Discovery

Founded 2017 Germany Dresden, Germany 8 employees Seed Biopharma, Biotechnology

General Information

Company Name DyNAbind GmbH
Founded Year 2017
Location Germany Dresden, Germany +1
Founders / Decision Makers
Team member
Employees 8
Industries Biopharma, Biotechnology
Funding Stage Seed
Social

Get notified when DyNAbind GmbH moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About DyNAbind GmbH

DyNAbind is a Germany-based startup that is revolutionizing drug discovery with its innovative DNA-Encoded Library platform. Founded in 2017, the company's slogan "Accelerating Drug Discovery" encapsulates its mission to provide fast, reliable, and high-quality medicinal chemistry starting points for various protein targets. The recent Seed Round investment at 08 May 2019 saw participation from notable investors including High-Tech Gründerfonds, TGFS - Technologiegründerfonds Sachsen, and TUDAG. DyNAbind's technology differentiates itself from traditional high-throughput screening methods by enabling simultaneous selection from hundreds of millions of molecules, offering superior signal-to-noise ratios, reduced false positive rates, and rapid hit validation. This approach significantly expedites the hit discovery process, delivering results in just a few weeks compared to over a year using conventional methodologies. The company prides itself on its customer focus, catering to diverse partners including big pharma, biotech, and academic groups. DyNAbind is poised to engage and collaborate with partners to tailor customized workflows and financial structures to meet specific discovery needs, showcasing a dynamic and customer-centric approach to its operations.

Taxonomy: Drug Discovery, DNA-Encoded Libraries, Small Molecule Discovery, Fragment-Based Discovery, Medicinal Chemistry, Pharmaceutical Research, Biotechnology Innovation, High-Throughput Screening, Protein Targets, Innovative Technology, Biotech Partnership, Academic Collaborations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 3
Investor Investor
•••• ••••
08 May 2019

DyNAbind GmbH Alternatives & Competitors

DyNAbind GmbH vs
AlphaMa
AlphaMa China

AlphaMa is a pioneering drug R&D company based on AI and DEL drug discovery innovation platform.

7 employees
DyNAbind GmbH vs
SyntheX
SyntheX United States

Targeting the undruggable with synthetic biology-based drug discovery platforms

Series Unknown
26 employees
Biotechnology, Health and Wellness
DyNAbind GmbH vs

Designing novel proteins, enzymes, and antibodies is limited by the problem of generating and screen...

2-10 employees
Biotechnology

FAQ About DyNAbind GmbH

Accelerating Drug Discovery
DyNAbind GmbH was founded in 2017.
DyNAbind GmbH is headquartered in Dresden, Germany.
DyNAbind GmbH operates in the following industries: Biopharma, Biotechnology.
DyNAbind GmbH has approximately 8 employees.
DyNAbind GmbH has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to DyNAbind GmbH include AlphaMa, SyntheX, Revolve Biotechnologies, Inc., Leash Bio, AI|ffinity. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DyNAbind GmbH and AlphaMa are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors DyNAbind GmbH and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy